Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR, 2002. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2 :209–218.
Plowe CV, 2005. Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Curr Top Microbiol Immunol 295 :55–79.
Hyde JE, 2005. Drug-resistant malaria. Trends Parasitol 21 :494–498.
Schlagenhauf P, Steffen R, Loutan L, 2003. Migrants as a major risk group for imported malaria in European countries. J Travel Med 10 :106–107.
Eliades MJ, Shah S, Nguyen-Dinh P, Newman RD, Barber AM, Roberts JM, Mali S, Parisse ME, Steketee R, 2005. Malaria surveillance–United States 2003. MMWR Surveill Summ 54 :25–40.
Parola P, Gazin P, Pradines B, Parzy D, Delmont J, Brouqui P, 2004. Marseille: a surveillance site for malaria from Comoros Islands. J Travel Med 11 :184–186.
Parola P, Soula G, Gazin P, Foucault C, Delmont J, Brouqui P, 2006. Fever in travelers returning from tropical areas: prospective observational study of 613 cases hospitalized in Marseille, France, 1999–2003. Travel Med Infect Dis 4 :61–70.
Ouledi A, 1995. Epidemiology and control of malaria in the Islamic Federal Republic of Comoros. Sante 5 :368–371.
Randrianarivelojosia M, Sahondra-Harisoa JL, Raharimalala LA, Raveloson A, Mauclere P, Ariey F, 2003. A network RER rooted on in vitro readout assays of Plasmodium falciparum sensitivity to chloroquine in the Indian Ocean Region. Sante 13 :95–100.
Parola P, Ranque S, Badiaga S, Niang M, Blin O, Charbit JJ, Delmont J, Brouqui P, 2001. Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother 45 :932–935.
Adehossi E, Parola P, Foucault C, Delmont J, Brouqui P, Badiaga S, Ranque S, 2003. Three-day quinine-clindamycin treatment of uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother 47 :1173.
Minodier P, Noel G, Salles MK, Retornaz K, Walters H, Combes JC, Garnier JM, 2005. Mefloquine versus halofantrine in children suffering from acute uncomplicated falciparum malaria. Arch Pediatr 12 (Suppl 1):S67–S71.
Pradines B, Hovette P, Fusai TH, Atanda L, Baret E, Cheval P, Mosnier J, Callec A, Cren J, Amalvict R, Gardair JP, Rogier C, 2006. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol 44 :2404–2408.
Musset L, Pradines B, Parzy D, Durand R, Bigot P, Le Bras J, 2006. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother 57 :110–115.
Parzy D, Doerig C, Pradines B, Rico A, Fusai T, Doury JC, 2007. Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing. Am J Trop Med Hyg 57 :646–650.
Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF, 1996. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg 55 :209–213.
Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D, 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344 :257–263.
Leder K, Tong S, Weld L, Kain KC, Wilder-Smith A, von Sonnenburg F, Black J, Brown GV, Torresi J, GeoSentinel Surveillance Network, 2006. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 43 :1185–1193.
Eichenlaub D, Pohle HD, 1980. A case of chloroquine-resistant (R1) falciparum malaria from the East African Comoros Island. Infection 8 :90–92.
Feuillet NP, Agnamey P, Brasseur P, Druilhe P, 1993. In vivo resistance of Plasmodium falciparum to chloroquine in Anjouan (Comoros). Bull Soc Pathol Exot 86 :48–51.
Randrianarivelojosia M, Raherinjafy RH, Migliani R, Mercereau-Puijalon O, Ariey F, Bedja SA, 2004. Plasmodium falciparum resistant to chloroquine and to pyrimethamine in Comoros. Parasite 11 :419–423.
Pettinelli F, Pettinelli ME, Eldin de Pecoulas P, Millet J, Michel D, Brasseur P, Druilhe P, 2004. High prevalence of multidrug-resistant Plasmodium falciparum malaria in the French territory of Mayotte. Am J Trop Med Hyg 70 :635–637.
Silai R, Moussa M, Abdalli Mari M, Astafieva-Djaza M, Hafidhou M, Oumadi A, Randrianarivelojosia M, Said Ankili A, Said Ahmed B, Gayibor AH, Ariey F, Ringwald P, 2007. Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros. Bull Soc Pathol Exot 100 :6–9.
Anonymous, 2006. Travelers’ health and advices for travelers. Bull Epidemiol Hebd 23–24 :154–163.
Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SL, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185 :380–388.
Pradines B, Mabika Mamfoumbi M, Tall A, Sokhna C, Hoeck JL, Fusai T, Mosnier J, Czarnecki E, Spiegel A, Trape JF, Kombila M, Rogier C, 2006. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother 50 :3225–3226.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 940 | 865 | 40 |
Full Text Views | 231 | 13 | 0 |
PDF Downloads | 66 | 11 | 0 |
A total of 248 Plasmodium falciparum isolates were sampled in travelers with malaria who came to Marseille, France from Comoros to investigate in vitro activities of antimalarial drugs and molecular markers of drug resistance. Of the 248 isolates, 126 were maintained in culture. Of these, 53% were resistant to chloroquine, and 3% had reduced susceptibility to quinine, mefloquine, and atovaquone; 1% had reduced susceptibility to halofantrine and dihydroartemisinin; 7% had reduced susceptibility to monodesethylamodiaquine; 37% had reduced susceptibility to cycloguanil; and none had reduced susceptibility to lumefantrine. Resistance-associated point mutations were screened in 207 isolates. No mutations in the cytochrome b gene were found. Of the 207 isolates, 119 (58%) had a mutation in the P. falciparum dihydrofolate reductase (Pfdhfr) gene at codon 108, 6 (5%) had mutations in both Pfdhfr codon 108 and the P. falciparum dihydropteroate synthase codon 437, and 115 (56%) had the chloroquine resistance–associated K76T mutation in the P. falciparum chloroquine resistance transporter gene. This study represents a unique opportunity to improve surveillance of P. falciparum drug resistance in Comoros with consequences for treatment and chemoprophylaxis guidelines.
Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR, 2002. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2 :209–218.
Plowe CV, 2005. Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Curr Top Microbiol Immunol 295 :55–79.
Hyde JE, 2005. Drug-resistant malaria. Trends Parasitol 21 :494–498.
Schlagenhauf P, Steffen R, Loutan L, 2003. Migrants as a major risk group for imported malaria in European countries. J Travel Med 10 :106–107.
Eliades MJ, Shah S, Nguyen-Dinh P, Newman RD, Barber AM, Roberts JM, Mali S, Parisse ME, Steketee R, 2005. Malaria surveillance–United States 2003. MMWR Surveill Summ 54 :25–40.
Parola P, Gazin P, Pradines B, Parzy D, Delmont J, Brouqui P, 2004. Marseille: a surveillance site for malaria from Comoros Islands. J Travel Med 11 :184–186.
Parola P, Soula G, Gazin P, Foucault C, Delmont J, Brouqui P, 2006. Fever in travelers returning from tropical areas: prospective observational study of 613 cases hospitalized in Marseille, France, 1999–2003. Travel Med Infect Dis 4 :61–70.
Ouledi A, 1995. Epidemiology and control of malaria in the Islamic Federal Republic of Comoros. Sante 5 :368–371.
Randrianarivelojosia M, Sahondra-Harisoa JL, Raharimalala LA, Raveloson A, Mauclere P, Ariey F, 2003. A network RER rooted on in vitro readout assays of Plasmodium falciparum sensitivity to chloroquine in the Indian Ocean Region. Sante 13 :95–100.
Parola P, Ranque S, Badiaga S, Niang M, Blin O, Charbit JJ, Delmont J, Brouqui P, 2001. Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother 45 :932–935.
Adehossi E, Parola P, Foucault C, Delmont J, Brouqui P, Badiaga S, Ranque S, 2003. Three-day quinine-clindamycin treatment of uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother 47 :1173.
Minodier P, Noel G, Salles MK, Retornaz K, Walters H, Combes JC, Garnier JM, 2005. Mefloquine versus halofantrine in children suffering from acute uncomplicated falciparum malaria. Arch Pediatr 12 (Suppl 1):S67–S71.
Pradines B, Hovette P, Fusai TH, Atanda L, Baret E, Cheval P, Mosnier J, Callec A, Cren J, Amalvict R, Gardair JP, Rogier C, 2006. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol 44 :2404–2408.
Musset L, Pradines B, Parzy D, Durand R, Bigot P, Le Bras J, 2006. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother 57 :110–115.
Parzy D, Doerig C, Pradines B, Rico A, Fusai T, Doury JC, 2007. Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing. Am J Trop Med Hyg 57 :646–650.
Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF, 1996. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg 55 :209–213.
Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D, 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344 :257–263.
Leder K, Tong S, Weld L, Kain KC, Wilder-Smith A, von Sonnenburg F, Black J, Brown GV, Torresi J, GeoSentinel Surveillance Network, 2006. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 43 :1185–1193.
Eichenlaub D, Pohle HD, 1980. A case of chloroquine-resistant (R1) falciparum malaria from the East African Comoros Island. Infection 8 :90–92.
Feuillet NP, Agnamey P, Brasseur P, Druilhe P, 1993. In vivo resistance of Plasmodium falciparum to chloroquine in Anjouan (Comoros). Bull Soc Pathol Exot 86 :48–51.
Randrianarivelojosia M, Raherinjafy RH, Migliani R, Mercereau-Puijalon O, Ariey F, Bedja SA, 2004. Plasmodium falciparum resistant to chloroquine and to pyrimethamine in Comoros. Parasite 11 :419–423.
Pettinelli F, Pettinelli ME, Eldin de Pecoulas P, Millet J, Michel D, Brasseur P, Druilhe P, 2004. High prevalence of multidrug-resistant Plasmodium falciparum malaria in the French territory of Mayotte. Am J Trop Med Hyg 70 :635–637.
Silai R, Moussa M, Abdalli Mari M, Astafieva-Djaza M, Hafidhou M, Oumadi A, Randrianarivelojosia M, Said Ankili A, Said Ahmed B, Gayibor AH, Ariey F, Ringwald P, 2007. Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros. Bull Soc Pathol Exot 100 :6–9.
Anonymous, 2006. Travelers’ health and advices for travelers. Bull Epidemiol Hebd 23–24 :154–163.
Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SL, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185 :380–388.
Pradines B, Mabika Mamfoumbi M, Tall A, Sokhna C, Hoeck JL, Fusai T, Mosnier J, Czarnecki E, Spiegel A, Trape JF, Kombila M, Rogier C, 2006. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother 50 :3225–3226.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 940 | 865 | 40 |
Full Text Views | 231 | 13 | 0 |
PDF Downloads | 66 | 11 | 0 |